FLINT, Mich., Oct. 2, 2019 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO), has appointed David Skomo as chief operating officer of
CastiaRx following the retirement of Chris
Luthin. CastiaRx, a division of Diplomat, is a pharmacy
benefit manager (PBM) that helps healthcare payers manage specialty
pharmacy costs.
Previously, Luthin and Skomo worked closely to develop
differentiated solutions for payers for their pharmacy and
specialty benefit challenges. CastiaRx remains committed to
investing in people, processes, technology, and infrastructure to
add value for clients and plan members.
Skomo joined CastiaRx in 2018 as a member of the leadership
team, most recently serving as the senior vice president of PBM
operations. During the past 14 months, Skomo has applied his
considerable skills and industry knowledge to transform key
operational areas of the company, notably mail-order prescription
fulfillment and contact-center operations.
"Dave has been instrumental in transforming our mail-order
business and contact-center operations to meet and exceed industry
standards," Diplomat CEO Brian
Griffin said. "His impressive background of leading process
improvement and offering guidance to enable technology-based
solutions has already been a great asset to CastiaRx."
With more than 25 years of pharmacy experience, Skomo's career
includes leadership roles in PBM, specialty pharmacy, and clinical
arenas. He is well-versed in CastiaRx processes and thoroughly
understands pharmacy operations and benefit management.
"Throughout my career I've had the opportunity to gain
incredible experiences in the industry," Skomo said. "I have
managed operations for CVS Caremark, and I've been part of
operational leadership teams for BriovaRx specialty pharmacy and
OptumRx. These positions have provided a broad knowledge base that
I look forward to continuing to apply to benefit CastiaRx."
About Diplomat
Diplomat (NYSE: DPLO) is the nation's largest independent
provider of specialty pharmacy and infusion services. Diplomat
helps people with complex and chronic health conditions in all 50
states, partnering with payers, providers, hospitals,
manufacturers, and more. Rooted in this patient-care expertise,
Diplomat also serves payers through CastiaRx, a leading specialty
benefit manager, and offers tailored solutions for healthcare
innovators through EnvoyHealth. Diplomat opened its doors in 1975
as a neighborhood pharmacy with one essential tenet: "Take good
care of patients and the rest falls into place." Today, that
tradition continues — always focused on improving patient care. For
more information, visit diplomat.is.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance and include Diplomat's
expectations regarding the new chief operating officer of CastiaRx
appointment and related transition, the expected benefits and
performance of business and growth strategies and impact of
operational improvement initiatives. The forward-looking statements
contained in this press release are based on management's
good-faith belief and reasonable judgment based on current
information. These statements are qualified by important risks and
uncertainties, many of which are beyond our control, that could
cause our actual results to differ materially from those forecasted
or indicated by such forward-looking statements. These risks and
uncertainties include: our ability to adapt to changes or trends
within the specialty pharmacy industry; the dependence on key
employees and effective succession planning and managing recent
turnover among key employees; potential disruption to our
workforce and operations due to cost savings and
restructuring initiatives; failure to effectively differentiate our
products and services in the PBM marketplace; maintaining existing
patients; the ability to identify and consummate strategic
alternatives that yield additional value for shareholders; the
timing, benefits and outcome of the Company's ongoing strategic
alternatives review process, including the determination of whether
or not to pursue or consummate any strategic alternative;
the structure, terms and specific risks and uncertainties
associated with any potential strategic transaction; potential
disruptions in our business and the stock price as a result of our
exploration, review and pursuit of strategic alternatives or the
public announcement thereof and any decision or transaction
resulting from such review, including potential disruptions with
respect to our employees, vendors, clients and customers; and the
additional factors set forth in "Risk Factors" in Diplomat's most
recent Annual Report on Form 10-K and in subsequent reports
filed with or furnished to the Securities and Exchange
Commission. Except as may be required by any applicable
laws, Diplomat assumes no obligation to publicly update such
forward-looking statements, which are made as of the date hereof or
the earlier date specified herein, whether as a result of new
information, future developments, or otherwise.
CONTACT:
Terri Anne
Powers, Vice President of Investor Relations
312.889.5244 | tpowers@diplomat.is
Jennifer Pavlovich, Corporate
Communications Manager
810.768.9282 | press@diplomat.is
View original content to download
multimedia:http://www.prnewswire.com/news-releases/diplomat-announces-promotion-of-david-skomo-to-chief-operating-officer-of-castiarx-300930063.html
SOURCE Diplomat Pharmacy, Inc.
